Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” (16 June 2026)
The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” held on 16 June 2026. This webinar included a lecture by Dr. Weida Tong (FDA) followed by a 30-minute Q&A...![[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]](https://cddf.org/wp-content/uploads/2026/06/Copy-of-PUBLICATION-Annual-Repport-2024-Is-available-6-1080x675.jpg)
[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]
ACT EU has developed the guideline to simplify the clinical trials application package for use during PHEs. The package consists of: 1️⃣ A guidance document on the simplified application package for clinical trials targeting a PHE 2️⃣ Annex I: Part I language...
CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova
🔔📢 CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova The Cancer Drug Development Forum (CDDF) is pleased to announce the appointment of Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova to its Board of Directors. We look forward to...